Recent Updates
Recently added Catalysts
VOR Positive Sentiment

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease

Wednesday, October 22, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vor Bio will host a live webcast on October 28, 2025, to discuss late-breaking Phase 3 clinical data for telitacicept in primary Sjögren’s disease. The presentation will include key efficacy and safety results from the trial conducted in collaboration with RemeGen Co., Ltd. The webcast will be accessible for replay on the company's investor website.
Price reaction · baseline $26.5 (2025-10-22 close) · hit after-hours · 1 other VOR headline(s) in the window, move may be shared
day 0 close · peak
+4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Vor Bio is presenting late-breaking Phase 3 data, indicating progress.
  • Collaboration with RemeGen Co., Ltd. enhances credibility.
  • The webcast features expert insights from a renowned rheumatology professor.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+442%
120-day peak, hindsight
Typical move
18.8%
average across 6 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
Telitacicept
Phase 3 · Primary Sjogren's Disease

Full Press Release Details

CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).
During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.

Webcast Details:

Date:Tuesday, October 28, 2025Time:4:30 PM Eastern Time

Access:

Replay:A replay of the webcast will be available via the investor section of the Company’s website athttps://ir.vorbio.com/events-presentations/approximately two hours after the call’s conclusion and will remain available for a period of 30 days.
About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visitwww.vorbio.com.

Media & Investor Contacts:Carl Mauchcmauch@vorbio.com

Frequently Asked Questions

When is the Vor Bio webcast on telitacicept data?

The webcast is scheduled for October 28, 2025, at 4:30 PM Eastern Time.

Who will present the Phase 3 data during the webcast?

Vor Bio management will present alongside Dr. Ronald van Vollenhoven.

What is telitacicept used for?

Telitacicept is being developed for the treatment of primary Sjögren’s disease.

How can I access the webcast replay?

The replay will be available on Vor Bio's investor website approximately two hours after the live call.

ShareAdd on Google
Tags: VOR Viatris Investor Conferences Healthcare Vor Bio telitacicept Sjögren’s disease Phase 3 RemeGen
Last updated: Oct 22, 2025

Biotech snapshot

Cash runway
$466M liquidity · $8M/mo burn
~55 mo
Minimal dilution risk
Lead asset
TelitaciceptPhase 3
Primary Sjogren's Disease →

Catalyst track record

+442%
best trade around VOR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VOR.

See every catalyst's timing & PoA →